Saghar Yousefnia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saghar Yousefnia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Morteza Abkar
Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran
3 shared publicationsArshia Yadollahi
Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran
2 shared publications- Ghasem Dini
Department of Nanotechnology, Faculty of Chemistry, University of Isfahan, Isfahan, Iran
2 shared publications Maryam Shirvani
Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran
2 shared publications- Negar Nasri
Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, 81746-73441, Iran
2 shared publications Shaghayegh Saharkhiz
Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan 81746-73441, Iran
2 shared publications
Latest Publications
- 9 July 2026
- Published by Springer Nature
- p. 655-668
Breast Cancer, Subtypes, Risk Factors, and Treatment
- 9 July 2026
- Published by Springer Nature
- p. 655-668
Breast Cancer, Subtypes, Risk Factors, and Treatment
- Open Access
- 4 July 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1)
Application of metal-based nanoparticles in targeted drug delivery to breast cancer stem cells
Breast cancer stem cells (BCSCs) are a minor population within breast cancer tissue, causing cancer development and cancer recurrence due to stem-like and malignant properties, including self-renewal, proliferation, differentiation, migration, invasion, metastasis, and resistance to chemo/radio therapy. Treatment of these types of cancer cells requires targeted approaches to address the unique properties of BCSCs. Metal nanoparticles (MNPs) can be applied as drug delivery nanosystems in the treatment of BCSCs. Breast cancer treatments by MNP-based targeted drug delivery are essential because they reduce patient discomfort and recovery time, while enabling more precise and targeted therapy, potentially reducing off-target effects when appropriately designed and dosed. The size, shape, surface characteristics, and unique properties of MNPs, including their optical and physicochemical characteristics, safety profiles that are highly dependent on particle design and administration parameters, stability, circulation half-life, biodistribution, and high drug release efficiency, make them highly reactive and versatile for a variety of biomedical applications. However, their safety profiles are strongly influenced by particle design, dosage, and administration parameters, as high concentrations may induce dose-dependent toxicity, including ROS-mediated cellular damage. This review focuses on applications of various MNPs, including gold, copper, iron oxide, and silver, their surface modifications, and combination with photothermal therapy and several therapeutic agents in the drug delivery of BCSCs. This review also highlights the advantages, current challenges, and prospects of MNPs in drug delivery systems. These promising approaches have significant potential for developing new strategies for invasive treatment of breast cancer.
- 4 July 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1)
Open AccessApplication of metal-based nanoparticles in targeted drug delivery to breast cancer stem cells
Breast cancer stem cells (BCSCs) are a minor population within breast cancer tissue, causing cancer development and cancer recurrence due to stem-like and malignant properties, including self-renewal, proliferation, differentiation, migration, invasion, metastasis, and resistance to chemo/radio therapy. Treatment of these types of cancer cells requires targeted approaches to address the unique properties of BCSCs. Metal nanoparticles (MNPs) can be applied as drug delivery nanosystems in the treatment of BCSCs. Breast cancer treatments by MNP-based targeted drug delivery are essential because they reduce patient discomfort and recovery time, while enabling more precise and targeted therapy, potentially reducing off-target effects when appropriately designed and dosed. The size, shape, surface characteristics, and unique properties of MNPs, including their optical and physicochemical characteristics, safety profiles that are highly dependent on particle design and administration parameters, stability, circulation half-life, biodistribution, and high drug release efficiency, make them highly reactive and versatile for a variety of biomedical applications. However, their safety profiles are strongly influenced by particle design, dosage, and administration parameters, as high concentrations may induce dose-dependent toxicity, including ROS-mediated cellular damage. This review focuses on applications of various MNPs, including gold, copper, iron oxide, and silver, their surface modifications, and combination with photothermal therapy and several therapeutic agents in the drug delivery of BCSCs. This review also highlights the advantages, current challenges, and prospects of MNPs in drug delivery systems. These promising approaches have significant potential for developing new strategies for invasive treatment of breast cancer.
- 27 September 2024
- Published by Springer Nature
- p. 1-14
Breast Cancer, Subtypes, Risk Factors, and Treatment
- 27 September 2024
- Published by Springer Nature
- p. 1-14
Breast Cancer, Subtypes, Risk Factors, and Treatment
- Open Access
- 29 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1384342
A comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells
Long non-coding RNAs (lncRNAs) are versatile RNAs that regulate various cellular processes, such as gene regulation, by acting as signals, decoys, guides, and scaffolds. A novel recognized lncRNA, LOXL1-antisense RNA 1 (LOXL1-AS1), is dysregulated in some diseases, including cancer, and acts as an oncogenic lncRNA in many types of cancer cells. Upregulation of LOXL1-AS1 has been involved in proliferation, migration, metastasis, and EMT, as well as inhibiting apoptosis in cancer cells. Most importantly, the malignant promoting activity of LOXL1-AS1 can be mostly mediated by sequestering specific miRNAs and inhibiting their binding to the 3´UTR of their target mRNAs, thereby indirectly regulating gene expression. Additionally, LOXL1-AS1 can decoy transcription factors and proteins and prevent their binding to their regulatory regions, inhibiting their mechanistic activity on the regulation of gene expression and signaling pathways. This review presents the mechanistic pathways of the oncogenic role of LOXL1-AS1 by modulating its target miRNAs and proteins in various cancer cells. Having information about the molecular mechanisms regulated by LOXL1-AS1 in cancer cells can open ways to find out particular prognostic biomarkers, as well as discover novel therapeutic approaches for different types of cancer.
- 29 July 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1384342
Open AccessA comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells
Long non-coding RNAs (lncRNAs) are versatile RNAs that regulate various cellular processes, such as gene regulation, by acting as signals, decoys, guides, and scaffolds. A novel recognized lncRNA, LOXL1-antisense RNA 1 (LOXL1-AS1), is dysregulated in some diseases, including cancer, and acts as an oncogenic lncRNA in many types of cancer cells. Upregulation of LOXL1-AS1 has been involved in proliferation, migration, metastasis, and EMT, as well as inhibiting apoptosis in cancer cells. Most importantly, the malignant promoting activity of LOXL1-AS1 can be mostly mediated by sequestering specific miRNAs and inhibiting their binding to the 3´UTR of their target mRNAs, thereby indirectly regulating gene expression. Additionally, LOXL1-AS1 can decoy transcription factors and proteins and prevent their binding to their regulatory regions, inhibiting their mechanistic activity on the regulation of gene expression and signaling pathways. This review presents the mechanistic pathways of the oncogenic role of LOXL1-AS1 by modulating its target miRNAs and proteins in various cancer cells. Having information about the molecular mechanisms regulated by LOXL1-AS1 in cancer cells can open ways to find out particular prognostic biomarkers, as well as discover novel therapeutic approaches for different types of cancer.
- Open Access
- 17 January 2024
- Published by Springer Nature in Research Square
Association of MT1A rs11640851, rs8052394 and rs11076161 polymorphisms with the risk of developing breast cancer: a haplotype-based case-control study and in silico analysis
Metallothionein 1A (MT1a) is involved in many pathological conditions associated with antioxidant defense and detoxification, including cancer. The aim of this study was to investigate the possible association of MT1A rs11640851, rs8052394, and rs11076161 single nucleotide polymorphisms (SNPs) with the risk of breast cancer (BC) and clinicopathological features. The study included 100 patients with BC and 100 healthy controls. We genotyped the MT1A SNPs using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and amplification refractory mutation system PCR (ARMS-PCR) techniques. The genotypic and allelic associations of MT1A SNPs with susceptibility to BC were assessed using logistic regression analysis under co-dominant, dominant, and recessive inheritance models. The combined effect of MT1A SNPs on the BC risk was determined using the haplotype analysis. In silico analysis was performed using the Polyphen-2 and RNAsnp online servers. The rs11640851 was found to be associated with a reduced risk of BC in all three inheritance models (P < 0.05). We also found that rs11640851 A allele has a protective effect against BC (OR: 4.812; 95% CI: 2.655–8.719; P < 0.0001). For rs8052394/rs11076161, carriers of AG/AA combined genotype had a 3.84-fold increased risk for developing BC. The haplotypes CAC and CGA were significantly associated with BC susceptibility. The rs11640851 was predicted to be deleterious using Polyphen-2 server. This study provides the first evidence that rs11640851 is significantly associated with a reduced risk of BC suggesting its protective role in the development of BC. Two haplotypes CAC and CGA were also identified as risk factors for BC.
- 17 January 2024
- Published by Springer Nature in Research Square
Open AccessAssociation of MT1A rs11640851, rs8052394 and rs11076161 polymorphisms with the risk of developing breast cancer: a haplotype-based case-control study and in silico analysis
Metallothionein 1A (MT1a) is involved in many pathological conditions associated with antioxidant defense and detoxification, including cancer. The aim of this study was to investigate the possible association of MT1A rs11640851, rs8052394, and rs11076161 single nucleotide polymorphisms (SNPs) with the risk of breast cancer (BC) and clinicopathological features. The study included 100 patients with BC and 100 healthy controls. We genotyped the MT1A SNPs using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and amplification refractory mutation system PCR (ARMS-PCR) techniques. The genotypic and allelic associations of MT1A SNPs with susceptibility to BC were assessed using logistic regression analysis under co-dominant, dominant, and recessive inheritance models. The combined effect of MT1A SNPs on the BC risk was determined using the haplotype analysis. In silico analysis was performed using the Polyphen-2 and RNAsnp online servers. The rs11640851 was found to be associated with a reduced risk of BC in all three inheritance models (P < 0.05). We also found that rs11640851 A allele has a protective effect against BC (OR: 4.812; 95% CI: 2.655–8.719; P < 0.0001). For rs8052394/rs11076161, carriers of AG/AA combined genotype had a 3.84-fold increased risk for developing BC. The haplotypes CAC and CGA were significantly associated with BC susceptibility. The rs11640851 was predicted to be deleterious using Polyphen-2 server. This study provides the first evidence that rs11640851 is significantly associated with a reduced risk of BC suggesting its protective role in the development of BC. Two haplotypes CAC and CGA were also identified as risk factors for BC.
- 30 May 2023
- Published by Springer Nature in Genes & Genomics
- Vol. 45 (9) , 1165-1178
Association of SOD2 rs2758339, rs5746136 and rs2842980 polymorphisms with increased risk of breast cancer: a haplotype-based case–control study
A growing body of evidence indicates that oxidative stress, high levels of reactive oxygen species (ROS), is implicated in the pathogenesis of breast cancer (BC). Superoxide dismutase (SOD2), a mitochondria-resident antioxidant enzyme, protects cells from ROS by catalytically converting the superoxide radicals into less reactive species. We aimed to investigate whether SOD2 rs2758339, rs5746136 and rs2842980 polymorphisms are associated with increased risk of BC. A total of 100 patients with BC and 100 healthy controls were enrolled in the study. We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay for genotyping the SOD2 single-nucleotide polymorphisms (SNPs). Under co-dominant, dominant and recessive inheritance models, the genotypic and allelic associations of SOD2 SNPs with susceptibility to BC were evaluated using logistic regression analysis. The haplotype analysis was performed on the SOD2 SNPs to determine their combined effect on the BC risk. We found that SOD2 rs5746136 was significantly associated with decreased risk of developing BC in co-dominant and dominant inheritance models (P < 0.05). The SOD2 rs5746136 T allele confers an apparent protective effect against breast carcinogenesis (OR: 1.956; 95% CI 1.312-2.916; P < 0.0001). The SOD2 rs5746136/rs2842980 combined genotypes (CT/AA, CT/AT and TT/AA) were significantly more frequent in healthy subjects compared to BC patients (P < 0.05). The CTA and ACA haplotypes (rs2758339, rs5746136, rs2842980) were found to be a protective and a risk factor for BC, respectively. These data strongly suggest that SOD2 rs5746136 was significantly associated with reduced risk of BC, indicating its protective role in BC development.
- 30 May 2023
- Published by Springer Nature in Genes & Genomics
- Vol. 45 (9) , 1165-1178
Association of SOD2 rs2758339, rs5746136 and rs2842980 polymorphisms with increased risk of breast cancer: a haplotype-based case–control study
A growing body of evidence indicates that oxidative stress, high levels of reactive oxygen species (ROS), is implicated in the pathogenesis of breast cancer (BC). Superoxide dismutase (SOD2), a mitochondria-resident antioxidant enzyme, protects cells from ROS by catalytically converting the superoxide radicals into less reactive species. We aimed to investigate whether SOD2 rs2758339, rs5746136 and rs2842980 polymorphisms are associated with increased risk of BC. A total of 100 patients with BC and 100 healthy controls were enrolled in the study. We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay for genotyping the SOD2 single-nucleotide polymorphisms (SNPs). Under co-dominant, dominant and recessive inheritance models, the genotypic and allelic associations of SOD2 SNPs with susceptibility to BC were evaluated using logistic regression analysis. The haplotype analysis was performed on the SOD2 SNPs to determine their combined effect on the BC risk. We found that SOD2 rs5746136 was significantly associated with decreased risk of developing BC in co-dominant and dominant inheritance models (P < 0.05). The SOD2 rs5746136 T allele confers an apparent protective effect against breast carcinogenesis (OR: 1.956; 95% CI 1.312-2.916; P < 0.0001). The SOD2 rs5746136/rs2842980 combined genotypes (CT/AA, CT/AT and TT/AA) were significantly more frequent in healthy subjects compared to BC patients (P < 0.05). The CTA and ACA haplotypes (rs2758339, rs5746136, rs2842980) were found to be a protective and a risk factor for BC, respectively. These data strongly suggest that SOD2 rs5746136 was significantly associated with reduced risk of BC, indicating its protective role in BC development.